Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 3/20 | 0.37 |
| ▸ | EDNRA | P25101 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339069 | 0.90 | ACHE (0.38) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL1167549 | 0.88 | MAPT (0.46) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL1167808 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL1168795 | 0.82 | MEN1 (0.41) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL10242362 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL1168099 | 0.82 | TUBB4A (0.46) | ALDH1A1MAPTMEN1KMT2ATHRB | |
| SCHEMBL412948 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL1168194 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL12338682 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EHPGDMEN1 | |
| SCHEMBL1168473 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4EHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090603-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8269017-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-03-10 | — | — | US | disclosed |
| US-7884094-B2 | antiproliferative agents such as 2-amino-N-(2-methoxy-5-[3- (3,4,5-trimethoxy-phenyl)- isoxazol-4-yl)-phenyl)-3- phenylpropanamide, that inhibit tubulin polymerization and/or target vasculature, usefeul for the treatment of cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884094-B2 | antiproliferative agents such as 2-amino-N-(2-methoxy-5-[3- (3,4,5-trimethoxy-phenyl)- isoxazol-4-yl)-phenyl)-3- phenylpropanamide, that inhibit tubulin polymerization and/or target vasculature, usefeul for the treatment of cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885MAPT 95/4885KDM4E 2492/4885 |
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885MAPT 95/4885KDM4E 2492/4885 |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885MAPT 95/4885KDM4E 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.